Focus on immunocompromised patients

Norovirus in immunocompromised patients.

W hile undergoing a routine mammogram, Mrs. B, age 76 years and in good health, was found to have right axillary adenopathy. A core biopsy confirmed the diagnosis of follicular lymphoma and she was referred to an oncologist who recommended treatment with six cycles of bendamustine, mitoxantrone, and rituximab. She tolerated the treatment fairly well except for mild lower abdominal discomfort fo...

Vaccines in immunocompromised patients.

Etiologic Agents of Candidemia in Pediatric Immunocompromised Patients

Abstract Background: Candidemia is the main cause of fungal nosocomial bloodstream infections and is related to meaningful mortality specially, in pediatrics. Mortality rate range from 5% to 71%, and it can reach as high as 81%. Delays in beginning of treatment have also been linked to intensified mortality. The epidemiology of Candida infection is changing from region to region. Regiona...

Antifungal Prophylaxis in Immunocompromised Patients

Invasive fungal infections (IFIs) represent significant complications in patients with hematological malignancies. Chemoprevention of IFIs may be important in this setting, but most antifungal drugs have demonstrated poor efficacy, particularly in the prevention of invasive aspergillosis. Antifungal prophylaxis in hematological patients is currently regarded as the gold standard in situations w...

Norovirus gastroenteritis in immunocompromised patients.

Copyright © 2012 Massachusetts Medical Society. Infectious gastroenteritis is a common, acute illness that is characteristically self-limiting, but it can become debilitating and life-threatening in immunocompromised patients.1 Noroviruses are major pathogens among the microbes associated with gastroenteritis in both immunocompetent and immunocompromised hosts1-4 (Table 1). In the United States...